

SPHHP Research Activities Newsletter

University at Buffalo

June/July 2019

IN THE NEWS

Congratulations to the Following Awardees!



Lucia Leone, Assistant Professor of Community Health and Health Behavior, is Co-I on a new award (PI: Stephanie Anzman-Frasco, Pediatrics) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development/NIH for the project entitled, *Promoting Healthier Meal Selection and Intake among Children in Restaurants*. The goal of the study is to establish the effectiveness of an in-restaurant intervention that is easy to implement and can be applied across restaurant contexts to promote healthier eating among children.



Kimberly Naus, Director of CAT Client Services, received a new award from the New York State Education Department for the project entitled, *2019-2023 Core Rehabilitation Services*. The program provides rehabilitation technology services, including assessments and trainings, for consumers in vocational rehabilitation for both education and employment.



Ekaterina Noyes, Professor of Epidemiology and Environmental Health, is PI on a continuation award from the National Cancer Institute/NIH for the project entitled, *Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC*. The study will continue to develop and test a novel intervention (Bright IDEAS- AC) to help improve health and function of cancer survivors by increasing utilization of cancer survivorship plans in a multi-site randomized pragmatic trial.



Gregory Wilding, Professor and Chair of Biostatistics, is Co-I on a continuation award (PI: Kathleen Tornatore, Pharmacy, Medicine) from the National Institute on Aging/NIH for the project entitled, *Age and Race Influences on Immunosuppression after Renal Transplant*. The study continues to seeks to improve immunosuppression by creating novel dosing that integrates age, race and sex with cellular and clinical endpoints, pharmacokinetics and pharmacogenomics to attain personalized medicine.



Guan Yu, Assistant Professor of Biostatistics, is Co-I on a continuation award from the National Institute of Dental & Craniofacial Research/NIH (Jill Kramer, PI, Oral Biology), for the project entitled, *Analysis of the Role of IgM in Sjogrens Syndrome (SS)*. The study will continue to identify the B cells subsets responsible for autoreactive IgM production in SS patients and to determine whether IgM is protective in the context of SS disease.

GRANT CLINIC

NIH Requests for Information

[NOT-NS-19-060](#)

Seeking Feedback on Research Priorities from SCI 2020: Launching a Decade of Disruption in Spinal Cord Injury (SCI) Research

Comments are solicited on the top priorities identified in the five SCI 2020 breakout sessions as summarized in the NIH Notice. Responders to this RFI are encouraged to provide input on how the research and research capacity building in the priority areas may be adopted in low resource settings including low- and middle-income countries. Responses to this RFI must be submitted electronically [here](#) by **July 31, 2019**.

Inside this issue:

| | |
|---------------------|-----|
| In the News | 1 |
| Grant Clinic | 1-3 |
| NIH Funding | |
| Limited Submissions | 3 |
| RFAs | 3-7 |
| PARs | 7-8 |
| Robert Wood Johnson | 8 |
| Words to Live By | 8 |

The Do's and Don'ts of Hyperlinks in NIH Grant Applications

The do's and don'ts of hyperlinks in grant applications are simple:

- **Do** include hyperlinks when explicitly requested in application guide, funding opportunity, or NIH Guide notice instructions
- **Do** use hyperlinks in relevant citations and publications included in biosketches and publication list attachments
- **Don't** use hyperlinks anywhere else in your application

Why does NIH limit the use of hyperlinks in grant applications?

- **Fairness.** Key sections of NIH grant applications – Specific Aims, Research Strategies, and Training Program Plans, to name a few – are page limited. Page limits promote fairness by ensuring all applicants have an equal opportunity to present their proposed project. Linking out to additional supporting information negates our page limits.
- **Reviewer Anonymity.** We instruct reviewers to rely on the information contained in the grant application and caution them not to follow unrequested links to websites. Website access, especially access to sites controlled by the institution or PI, can be tracked and can compromise reviewer anonymity.
- **Security.** Just like clicking on links in phishing emails, following links in grant applications can expose a reader to viruses, malware, or other security threats that can compromise our ability to protect application information.

NIH may withdraw your application from consideration if you include them. Don't risk it.

NIH Notices

[NOT-DA-19-046](#)

Notice of Webinar for “Digital Health Technologies to Address the Social Determinants of Health in the Context of Substance Use Disorders” (RFA-DA-20-017; RFA-Da-20-018)

Five informational webinars will be offered that cover various topics related to the RFA and submitting a competitive application. Webinars will be held on Tuesdays and Thursdays. Please refer to the NIH Notice for topic dates and times. [Frequently asked questions](#) are available to assist applicants and can answer many basic questions about the program.

[NOT-OD-19-110](#)

Guidance on Posting Informed Consent Forms for NIH-Funded Clinical Trials

For clinical trials conducted by or supported by a Federal department or agency, the Revised Common Rule requires the posting of an IRB-approved consent form on a public federal website designated for posting such consent forms.

- **NIH-funded recipients using an English-language informed consent form to enroll participants may either:** Submit an IRB-approved English-language informed consent form to [ClinicalTrials.gov](#). Documents that are uploaded to ClinicalTrials.gov should be uploaded in accordance with the instructions at <https://prsinfo.clinicaltrials.gov/>. Or: Submit an IRB-approved informed consent form to Regulations.gov following the instructions in the paragraph below
- **NIH-funded recipients using only non-English informed consent forms to enroll participants:** Submit an IRB-approved informed consent form to [Docket ID: HHS-OPHS-2018-0021](#) on the Regulations.gov website in accordance with guidance issued by the Office for Human Research Protections at <https://www.hhs.gov/ohrp/regulations-and-policy/informed-consent-posting/index.html>. NIH recipients submitting informed consent forms to Regulations.gov should maintain a copy of their Regulations.gov receipt and tracking number.

[NOT-HL-19-695](#)

Notice of Special Interest: Understanding Factors in Infancy and Early Childhood (Birth to 24 months) that Influence Obesity Development

NHLBI is interested in supporting mechanistic trials related to the development of obesity in children aged 0-24 months under this funding opportunity. NHLBI encourages research applications that aim to delineate behavioral, biological, psychosocial, and/or environmental factors and their potential interactions that increase or mitigate the risk of obesity from birth to 24 months. Bi-directional influences between the child, caregivers/parents, and environment are of interest. Please refer to the NIH Notice for submission details.

[NOT-OD-19-108](#)

Required Use of the xTRACT System to Prepare Data Tables for Training Grant Research Performance Progress Reports in FY2020

Beginning with RPPRs due on or after **October 1, 2019** (FY 2020), recipients must create the required training data tables for submission with NIH and AHRQ T15, T32, T90/R90, and TL1 progress reports via the xTRACT system. System validations in the RPPR module will check to ensure that uploaded PDFs of the data tables were created via xTRACT, and users will not be able to submit RPPRs that are not in compliance. Guidance on preparing the required tables for the RPPR are available in the [xTRACT User Guide](#) and on the [Data Tables](#) website.

Notices of Intent to Publish a Funding Opportunity Announcement

Consortium on the Neurobiology of Adolescent Drinking in Adulthood – anticipated release October 1, 2019

[NOT-AA-19-016](#)

Research Projects (U01); expected due date December 1, 2019

[NOT-AA-19-017](#)

Administrative Resource (U24); expected due date December 2, 2019

[NOT-AA-19-018](#)

Research Resource (U24); expected due date December 2, 2019

[NOT-DA-19-047](#)

The National Drug Abuse Treatment Clinical Trials Network (UG1); anticipated release August 1, 2019; expected due date: November 1, 2019

[NOT-MD-19-024](#)

Specialized Centers of Excellence on Environmental Health Disparities (P50); anticipated release August 1, 2019; expected due date November 15, 2019

NIH FUNDING OPPORTUNITIES

LIMITED SUBMISSIONS

Prior approval from UB is required for the following funding opportunities. If you are interested in applying to any of the **limited submissions** listed below, please provide the OVPRED with notification through the [Limited Submissions Mailbox](#) at least 60 days prior to the sponsor's submission deadline before proceeding with an application. The limited submission program is managed by Dr. Kenneth Tramposch on behalf of the OVPRED. He may be contacted at kmt1@buffalo.edu or by phone at 645-3321 for any questions or advice about the limited submission process.

[RFA-DK-19-002 \(P30\)](#) – clinical trial optional

Nutrition Obesity Research Centers (NORCs)

The mission of the NORC program is to serve as a key component of the NIDDK-supported research effort to advance nutrition and obesity research. The NORCs promote new discoveries and enhance scientific progress through support of cutting-edge basic, clinical, and translational research in nutrition science and obesity with the ultimate goal of improving public health. *Only one application per institute is allowed.* **Application Due Date:** October 23, 2019

RFA: REQUESTS FOR APPLICATIONS

August Due Dates

[RFA-CA-19-032 \(R01\)](#) – clinical trial optional

Provocative Questions (PQs) in Cancer with an Underlying HIV Infection

The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or AIDS. Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Please refer to the FOA for the six PQs. **Application Due Date:** August 1, 2019

[RFA-HG-19-013 \(U01\)](#) – Clinical Sites – clinical trial required for all RFAs

[RFA-HG-19-014 \(U01\)](#) – Enhanced Diversity Clinical Sites; [RFA-HG-19-015 \(U01\)](#) – Coordinating Center

The Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network

These FOAs invite applications to participate in the Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network. The network will use biorepositories linked to electronic medical records (EMRs) for genomic research by developing, evaluating, and disseminating genomic risk assessment and management tools for clinical use. **Application Due Date:** August 2, 2019

[RFA-DA-20-016 \(U01\)](#) – clinical trial optional

National Drug Early Warning system Coordinating Center

This FOA seeks applications to assess the current availability of data relevant to the understanding and early detection of drug abuse patterns and trends across selected sentinel areas. This initiative aims to identify a set of key indicators of drug availability; use and associated consequences with the objective of developing approaches to harmonizing data; analysis and presentation across sentinel areas in order to monitor patterns of use of illicit drugs (including nonmedical use of prescription medications); and associated consequences. **Application Receipt Date:** August 14, 2019

[RFA-RM-19-006 \(DP2\)](#) – clinical trial optional

NIH Directors New Innovator Award Program

This program is designed to support unusually creative investigators with highly innovative research ideas at an early stage of their career when they may lack the preliminary data required for an R01 grant application. The emphasis is on innovation and creativity; preliminary data are not required but may be included. The review process emphasizes the individual's creativity, the innovativeness of the research approaches, and the potential of the project, if successful, to have a significant impact on an important biomedical or behavioral research problem.

Application Due Date: August 26, 2019

[RFA-ES-19-010 \(R25\)](#) – clinical trial not allowed

Undergraduate Research Education Program (UP) to Enhance Diversity in the Environmental Health Sciences

The goal of this NIEHS undergraduate research education R25 program is to support research educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce in the environmental health sciences. To this end, this FOA encourages the development of creative educational activities with a primary focus on research experiences for undergraduates at the junior and senior level. **Application Due Date:** August 30, 2019

September Due Dates

[RFA-MH-20-120 \(R01\)](#) – clinical trial not allowed

BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data

This FOA encourages secondary analysis of the large amounts of existing data related to the BRAIN Initiative. The data do not need to be held in one of the funded BRAIN Initiative data archives, but the data must be held in a data archive that is readily accessible to the research community. Support will be provided for innovative analysis of relevant existing datasets using conventional or novel analytic methods, data science techniques, and machine learning approaches.

Application Due Date: September 6, 2019

[RFA-RM-19-005 \(DP1\)](#) – clinical trial optional

NIH Directors Pioneer Award Program

This award supports individual scientists of exceptional creativity who propose highly innovative and potentially transformative research towards the ultimate goal of enhancing human health. The potential for impact on human health may be near term (clinical or translational research) or long term (basic research). The paramount features of the research proposed must be innovation and magnitude of potential impact. **Application Due Date:** September 9, 2019

[RFA-FD-20-002 \(UC2\)](#) – clinical trial not allowed

Cigar Tobacco Reference Products Program

This program seeks to develop a cigar tobacco reference products program that will require significant collaboration and research efforts with outside organizations. The selected organization(s) will develop tobacco reference products representing at minimum three categories of commercially available cigars to be used for investigational nonclinical purposes by tobacco manufacturers, contract and government laboratories, and academic institutions.

Application Receipt Date: September 10, 2019

[RFA-RM-19-008 \(DP5\)](#) – clinical trial optional

NIH Directors Early Independence Awards

This award supports exceptional investigators who wish to pursue independent research essentially after completion of their terminal doctoral/research degree or end of post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.

Application Due Date: September 13, 2019

[RFA-RM-19-007 \(R01\)](#) – clinical trial optional

NIH Directors Transformative Research Awards

This Award supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this FOA.

Application Due Date: September 20, 2019

[RFA-CA-19-019 \(R21\)](#) – clinical trial not allowed

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research

The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology.

Application Due Dates: September 27, 2019

[RFA-CA-19-020 \(R33\)](#) – clinical trial not allowed

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research

This FOA solicits applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. **Application Due Dates:** September 27, 2019

[RFA-CA-19-021 \(R21\)](#) – clinical trial not allowed

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research

This FOA solicits applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions.

Application Due Dates: September 27, 2019

[RFA-CA-19-022 \(R33\)](#) – clinical trial not allowed

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research

This FOA solicits applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Application Due Dates: September 27, 2019

October Due Dates

[RFA-HL-17-022 \(R21\)](#)

Maximizing the Scientific Value of the NHLBI Biorepository: Scientific Opportunities for Exploratory Research

This FOA will support meritorious exploratory research relevant to the [NHLBI mission](#) using the existing biospecimen collections that are stored in the NHLBI Biologic Specimen Repository, thereby maximizing the scientific value of the stored collections and providing researchers with an opportunity to generate preliminary data for subsequent research proposals. **Application Due Dates:** October 17, 2019

[RFA-AG-20-022 \(R01\)](#) – clinical trial optional

Aging, Driving and Early Detection of Dementia

This FOA invites applications to conduct new research on automobile technology for signaling early signs of cognitive impairment in older drivers. Two general kinds of research are envisioned: 1. Basic – intended to identify unobtrusive technology for monitoring driving performance and integrating it with other data to detect cognitive impairment, and 2. Methodological - intended to integrate driving-related data (and databases) with data on an individual's health and functional status to detect cognitive impairment. **Application Due Date:** October 22, 2019

[RFA-AG-20-006 \(R01\)](#) – clinical trial optional

Interpersonal Processes in Alzheimer's Disease and Related Dementias: Clinical Interactions and Care Partnerships

The goal of this initiative is to support research that can lead to the development of interventions for optimizing communication among patients, caregivers, and healthcare practitioners and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD.

Application Due Date: October 23, 2019

[RFA-NS-19-031 \(P50\)](#) – clinical trial optional

Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC)

These Centers promote collaborative basic, translational and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The Centers also provide outstanding environments for the training of new researchers capable of addressing high priority research objectives in the muscular dystrophies.

Application Due Date: October 31, 2019

November Due Dates

[RFA-DA-20-013 \(R01\)](#) – clinical trial optional

PrEP for HIV Prevention among Substance Using Populations

NIDA is interested in research that addresses research gaps related to PrEP and its use among substance users, with the goals of improving PrEP management and implementation. Only one clinical trial has evaluated PrEP among people who inject drugs and systematic data regarding the broader use of PrEP among substance users are limited. There is a need to better understand the effects of substance use on PrEP effectiveness and better inform PrEP implementation among substance users. **Application Due Date:** November 8, 2019

[RFA-AI-19-045 \(UM1\)](#) – clinical trial required

HIV/AIDS Clinical Trials Units

Applications are solicited for Clinical Trials Units to provide scientific and administrative expertise as well as the infrastructure to conduct clinical studies developed by NIH HIV/AIDS Clinical Trials Networks. Clinical Trials Units will participate in the development of trials and provide clinical sites, local laboratory capacity, and pharmacy support for two or more HIV/AIDS Clinical Trials Networks. **Application Due Date:** November 18, 2019

[RFA-CA-19-039 \(U01\)](#) – clinical trial optional

Early-Stage Development of Informatics Technologies for Cancer Research and Management

This FOA invites applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum and focuses on early-stage development from prototyping to hardening and adaptation. **Application Due Date:** November 20, 2019

[RFA-CA-19-040 \(U24\)](#) – clinical trial optional

Advanced Development of Informatics Technologies for Cancer Research and Management

This FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field.

Application Due Dates: November 20, 2019

[RFA-CA-19-041 \(U24\)](#) – clinical trial optional

Sustained Support for Informatics Technologies for Cancer Research and Management

The focus of this FOA is on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by the companion FOAs.

Application Due Dates: November 20, 2019

Multiple Due Dates

[RFA-NS-18-043 \(R01\)](#); [RFA-NS-18-042 \(R21\)](#) – clinical trial not allowed

Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment

These FOAs promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. **Application Due Dates:** July 11, 2019; November 12, 2019

[RFA-OD-18-005 \(K01\)](#) – clinical trial not allowed; [RFA-OD-18-006 \(K01\)](#) – clinical trial required

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research

These FOAs provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. **Application Due Dates:** July 19, 2019, November 8, 2019

[RFA-OD-18-007 \(K99/R00\)](#) – clinical trial not allowed; [RFA-OD-18-008 \(K99/R00\)](#) – clinical trial required

Pathway to Independence Award in Tobacco Regulatory Research

The purpose of this award is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. **Application Due Dates:** July 19, 2019, November 8, 2019

[RFA-ES-16-005 \(R21\)](#)

Mechanism for Time-Sensitive Opportunities in Environmental Health Sciences

This FOA supports environmental health research in which an unpredictable event provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation is to understand the consequences of natural and man-made disasters or emerging environmental public health threats in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding (substantially shorter than the typical NIH grant review/award cycle) in order for the research question to be addressed and swiftly implemented. **Application Due Dates:** August 1, 2019; September 3, 2019

[RFA-HL-19-023 \(T32\)](#) – clinical trial not allowed

T32 Training Program for Institutions that Promote Diversity

This program supports predoctoral and health professional students and individuals in postdoctoral training institutions with an institutional mission focused on serving health disparity populations not well represented in scientific research, with the potential to develop meritorious training programs in cardiovascular, pulmonary, and hematologic diseases, and sleep disorders.

Application Due Dates: September 4, 2019; February 26, 2020; September 4, 2020; February 26, 2021

[RFA-HL-19-024 \(R25\)](#) – clinical trial not allowed

Short-Term Research Education Program to Increase Diversity in Health-Related Research

This program supports educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce by providing research experiences and related opportunities that enrich the pool of individuals from nationally underrepresented groups who will be available to compete for research opportunities in the mission areas of importance to NHLBI. **Application Due Dates:** September 10, 2019, February 26, 2020, September 10, 2020, February 26, 2021

[RFA-DA-19-019 \(R43/R44\); RFA-DA-19-020 \(R41/R42\)](#) – clinical trial optional

America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis

These FOAs invite applications from US small business concerns to develop technologies to provide science-and research-based solutions to the opioid emergency.

Application Due Dates: September 8, 2019, April 9, 2020, September 8, 2020, April 9, 2021, September 8, 2021

[RFA-HL-20-003 \(UG3/UH3\)](#) – clinical trial optional; [RFA-HL-20-004 \(U24\)](#) – clinical trial not allowed

Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR)

The UG3/UH3 invites applications for projects that propose to test late-stage (T4) implementation research strategies for optimally and sustainably delivering proven-effective, evidence-based multi-level interventions to reduce or eliminate cardiovascular and/or pulmonary health disparities, and that promote and improve population health in high-burden communities. The U24 invites applications for a Research Coordinating Center (RCC) to support projects from the UG3/UH3. The RCC will coordinate activities across all of the DECIPHeR projects.

Application Due Date: October 1, 2019

[RFA-HL-19-025 \(K01\)](#) – clinical trial required; [RFA-HL-19-026 \(K01\)](#) – clinical trial not allowed

Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research

These FOAs are targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

Application Due Dates: October 10, 2019, February 11, 2020, October 9, 2020, February 11, 2021

[RFA-CA-19-034 \(P20\)](#) – clinical trial optional

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities

The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. **Application Due Dates:** October 18, 2019, June 19, 2020, and October 18, 2020

PAR: PROGRAM ANNOUNCEMENTS REVIEWED BY AN INSTITUTE

[PAR-19-279 \(R01\); PAR-19-280 \(R21\)](#) – clinical trial optional

Provocative Questions (PQs) in Multiple Myeloma Disparities Research

NCI invites applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research. The FOAs include six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions.

Application Due Dates: July 15, 2019; November 15, 2019; July 15, 2020; November 15, 2020

[PAR-19-283 \(D43\)](#) – International Research Training Grant - clinical trial optional

[PAR-19-285 \(G11\)](#) – Extramural Associate Research Development Award - clinical trials not allowed

HIV Research at Low-and Middle-Income Country Institutions

These FOAs encourage collaborative applications from U.S. and LMIC institutions for research training programs to strengthen the scientific capacity of LMIC institutions to conduct HIV research relevant to the evolving HIV epidemic in their country. **Application Due Dates:** August 20 2019, August 20, 2020, August 20, 2021

[PAR-19-282 \(R61/R33\)](#) – clinical trial optional

Exploratory Clinical Neuroscience Research on Substance Use Disorders

This FOA uses Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD), including fundamental brain function relevant to substance use.

Application Due Dates: October 10, 2019; July 10, 2020; March 10, 2021; October 13, 2021; July 11, 2022; March 10, 2023

[PAR-19-294 \(R01\)](#) – clinical trial not allowed

Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK

This FOA support early-stage preclinical validation of therapeutic leads such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. At the end of the project period, a successful project will have provided a significant contribution to the data supporting the validity around a therapeutic such that it can advance further through other funding mechanisms, such as the small business program

Application Due Dates: November 12, 2019, July 14, 2020, November 12, 2020, July 14, 2021, and November 12, 2021

FUNDING OPPORTUNITIES: FOUNDATIONS

Robert Wood Johnson Foundation

The [Heathy Eating Research](#) program aims to provide advocates, decision-makers, and policymakers with the evidence needed to address the key social determinants of health and inequalities that underlie poor dietary patterns and related health consequences. This program will support research that advances health equity in the areas of nutritional disparities, nutrition, and food security. Three types of grants will be awarded: 1. Small-scale (up to \$200,000 for 18 mths); 2. Large-scale (up to \$320,000 for up to 24 mths); and 3. CBPR grants (up to \$320,000 for up to 24 mths). An optional webinar will be held on **June 25th, 3-4pm, ET**. Registration is required [through this link](#).

Application Due Date: Concept Papers - July 31st, 3pm ET
Invited Applications - October 2, 2019, 3pm ET

[Equity-Focused Policy Research](#)—Building Evidence on Access to Early Care & Education for Low-Income Families supports action-orientated research that advances health equity, builds the knowledge base, and informs policymaking to increase **access to early care and education (ECE)** for low-income families. ECE is defined as formal and informal nonparental care for children birth to age 5. Approximately 10 awards will be funded, ranging from \$50,000 to \$500,000 each. An optional webinar will be held on **June 27th, 2-3pm ET**. [Registration](#) is required.

Application Due Date: Brief Proposals—July 25th, 3pm ET
Invited Applications: October 10th, 3pm ET

“It has been my observation that most people get ahead during the time that others waste.”

Henry Ford (1863-1947)

